IPAC Publications and Other Resources

"Experience suggests that it is important to preserve access to the full range of inhalation therapies to allow patients and prescribers the widest choice of treatment.  This is particularly important given the individualistic nature of asthma and COPD and the myriad of factors influencing choice of the appropriate treatment regimen for patients with these complex, idiosyncratic disease.  In addition, any reduction in the manufacture of HFC-based inhalers in the developed world threatens future supply in the developing world."


JDA, Choice in Inhalation Therapy, p. 58, 2004 PJB Publications Ltd., UK – JDA 33.